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M. Bevan showed in the mid-seventies that cytotoxic T
lymphocyte (CTL) responses may be initiated by antigen-
presenting cells that do not express the antigens themselves
(1). He called this process cross-priming. The antigen-pre-
senting cells involved in cross-priming must therefore inter-
 
nalize and present antigens to CD8
 
 
 
 T cells in the context
of MHC class I molecules. This process is often referred to
as “cross-presentation.” Cross-presentation by antigen-pre-
senting cells in vivo results in either cross-priming (initia-
tion of CD8
 
 
 
 T cell responses) or in cross-tolerance (in-
duction of CD8
 
 
 
 T cell unresponsiveness; reference 2).
These results raised the question of the nature of the “cross-
presenting cells.” In vitro, dendritic cells cross-present anti-
gens more efficiently than any other antigen-presenting cell
(3). They are also the only antigen-presenting cells that ac-
tivate naive T lymphocytes (4). Dendritic cells, indeed, are
sufficient for cross-presentation in vivo (5).
 
Fc Receptors (FcRs) and Cross-Presentation in Dendritic
Cells.
 
If cross-presentation is how dendritic cells initiate
CTL responses, antigen targeting to and internalization by
dendritic cells must represent a critical step in cross-prim-
ing. In vitro, targeting antigens to receptors for the Fc re-
gion (Fc
 
 
 
R) of IgG, dramatically increases the efficiency of
cross-presentation (3).
Fc
 
 
 
Rs are a family of membrane glycoproteins expressed
on hematopoietic cells (6). Most Fc
 
 
 
Rs do not bind IgG,
unless IgGs are themselves bound to multivalent-specific
antigens (i.e., immune complexes). Thus, Fc
 
 
 
RII (CD32)
and Fc
 
 
 
RIII (CD16) bind monomeric IgG quite ineffi-
ciently, but bind immune complexes with very high affin-
ity. Fc
 
 
 
RI (CD64), in contrast, binds monomeric IgG with
high affinity, but, like high affinity receptors for IgE, it
does not signal unless IgGs are cross-linked by their specific
polymeric ligands. Thus, Fc
 
 
 
Rs may be functionally con-
sidered as antigen receptors.
 
Targeting antigens to Fc
 
 
 
R promotes cross-presentation
by several orders of magnitude in mouse bone marrow–
derived dendritic cells (7, 8). The intracellular mechanisms
leading to cross-presentation after Fc
 
 
 
R-mediated uptake
have been analyzed. In dendritic cells, but not in other cell
types, Fc
 
 
 
R-mediated internalization very efficiently tar-
gets antigen for a unique dendritic cell–specific antigen
transport pathway resulting in delivery to the cytosol.
Once in the cytosol, internalized antigens are degraded by
the proteasome. The resulting peptides are translocated
into the lumen of the ER and loaded on MHC class I mol-
ecules (9). These results suggested that antigen-specific hu-
moral immune responses may promote the generation of
specific CTLs.
 
Protective Roles of Antitumor Abs In Vivo.
 
In the course
of most CTL-mediated immune responses, including anti-
tumor immune responses, specific Abs are also produced.
The biological role of these Abs, however, is poorly under-
stood. In the past few years, the relative efficacy of antitu-
mor Abs for the treatment of certain breast cancers or B cell
lymphomas, renewed the interest of immunologist in anti-
tumor humoral responses (10). The Abs used in the clinic
are directed against Her2/neu (a cellular proto oncogene,
trastuzumab) and CD20 (a B cell marker, rituximab). They
interfere with tumor growth in vitro, but their mechanism
of action in vivo is not fully understood.
In mice, antimelanoma Abs inhibit tumor growth in a
Fc
 
 
 
R-dependent manner (11). Human tumor treatment in
a mouse model with trastuzumab or rituximab is indepen-
dent on T cells, but requires activation Fc
 
 
 
Rs and is lim-
ited by inhibitory Fc
 
 
 
Rs (12). The main mechanism of Ab
treatments was, most likely, Ab-dependent cellular cyto-
toxicity (ADCC). It is also most likely that ADCC also
represents the main effector mechanism of Ab-based thera-
pies in cancer patients.
These results, however, do not exclude the possibility
that antitumor Abs induce specific CTL responses by pro-
moting dendritic cell–mediated cross-presentation of tumor
antigens. CD8
 
 
 
 CTL responses were indeed found in
mAb-based therapy of solid tumors in mice. Dyall et al.
showed that CD8
 
 
 
 T cell depletion in vivo prevents treat-
ment of established solid tumors with antitumor mAbs
(13). Therefore, antitumor Abs may also induce effective
CTL responses in vivo. Tumor-specific CTLs, however,
have not yet been reported in Ab-treated cancer patients.
In vitro experiments described in this issue by K.M.
Dhodapkar and colleagues (14), suggest a role for antitu-
mor Abs in the induction of antitumor CTLs. Coating of
myeloma cells with anti–syndecan-1 Abs did not increase
phagocytosis by dendritic cells. By contrast, cross-presenta-
tion of two tumor antigens (NY-ESO1 and MAGE3) and
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specific CTL cross-priming were strongly enhanced. Cross-
presentation after opsonized tumor cell phagocytosis re-
quired Fc
 
 
 
Rs and was more efficient for cross-priming
than phagocytosis of apoptotic cells, tumor cell lysates, or
treatment with synthetic peptides.
These results may both modify our understanding of
antitumor humoral responses, and, most likely, encourage
new approaches for dendritic cells loading with tumor
antigens for active cancer immunotherapy. Different
methods allow to sensitize dendritic cells with total tumor
antigens: tumor cell lysates, apoptotic tumor cells, tumor
cell–derived exosomes, and total tumor cell RNA. Few
studies, however, directly compared the efficiency of CTL
priming using these different dendritic cell sensitization
methods. The present results should encourage the use of
Ab-coated tumor cells for dendritic cell sensitization in
cancer immunotherapy.
 
Fc
 
 
 
Rs, Cross-Presentation, and Autoimmunity.
 
Like in
cancer, in most autoimmune diseases, including those with
pathogenic CTLs, abundant pathogenic autoAbs are also
produced. These Abs bind to either soluble autoantigens or
self-tissue fragments, thus forming immune complexes,
which may engage FcRs. In the past 10 years, the genera-
tion of mice lacking one or several Fc
 
 
 
Rs, demonstrated
their role in different autoimmune diseases (6).
Two types of Fc
 
 
 
R exist in both human and mouse: ac-
tivation and inhibitory Fc
 
 
 
R. Activation Fc
 
 
 
Rs signal
through an amino acid motif, called immunoreceptor tyro-
sine–based activation motifs, found in the cytosolic domain
of the receptor itself (for Fc
 
 
 
RIIA), or on the FcR-associ-
ated 
 
 
 
 chain (for Fc
 
 
 
RI and Fc
 
 
 
RIII). Activation Fc
 
 
 
Rs
include mouse and human Fc
 
 
 
RI, human Fc
 
 
 
RIIA, and
Fc
 
 
 
RIII. Mouse and human Fc
 
 
 
RII isoforms other than
Fc
 
 
 
RIIA, inhibit cell activation through immunoreceptor
tyrosine–based inhibitory motifs when cocross-linked to
activation receptors (Fc
 
 
 
Rs or many other receptors, in-
cluding B and T cell receptors). All Fc
 
 
 
Rs, but one iso-
form of Fc
 
 
 
RII (the B1 isoform), very efficiently internal-
ize their ligands.
Deletion of activation Fc
 
 
 
Rs protects against immune
complex–induced inflammation (6). Inhibitory Fc
 
 
 
Rs (Fc-
 
 
 
RIIB) knockout mice, by contrast, are more susceptible
to immune complex–induced inflammation, which favors
autoimmunity (including glomerulonephritis, collagen-induced
arthritis, and hemolitic anemia, for example). Inhibitory
Fc
 
 
 
RIIB is thought to maintain peripheral B cell tolerance
by blocking B cell activation when FDC present immune
complexes to specific B cells in germinal centers.
Also in this issue, H. Kita et al. (15), propose a novel role
for FcR-mediated cross-presentation in primary biliary cir-
rhosis (PBC). The authors identified a CD8
 
 
 
 T cells
epitope in the E2 component of pyruvate dehydrogenase
(PDC-E2), and showed that the frequency of CTL precur-
sors for this epitope is increased in PBC patients. FcR-
mediated internalization of PDC-E2 complexed to Abs by
dendritic cells results in effective cross-presentation to spe-
cific CD8
 
 
 
 T cell clones. Importantly, anti–PDC-E2 Abs
purified from patient’s sera also promoted efficient cross-
presentation, suggesting the involvement of autoAbs in the
pathogenesis of this autoimmune disease: in promoting
cross-presentation by dendritic cells, auto Abs could either
participate to breaking CD8
 
 
 
 T cell tolerance, or to the
amplification and development of ongoing autoimmune
CTL responses. These findings should focus our attention
on Fc
 
 
 
R expression and function on dendritic cells from
patients bearing CTL-dependent autoimmune diseases.
 
Cross-Priming, Cross-Tolerance, and Fc
 
 
 
R-induced Dendritic
Cell Maturation.
 
One critical aspect of Fc
 
 
 
R function in
dendritic cells, is the induction of maturation. In mouse
dendritic cells, engagement of either Fc
 
 
 
RI or Fc
 
 
 
RIII in-
duces maturation in an FcR-associated 
 
 
 
 chain–dependent
manner (7). In the studies published here, however, the au-
thors did not see Fc
 
 
 
R-mediated induction of dendritic
cell maturation. This discrepancy could, of course, be due
to species differences in Fc
 
 
 
R function in mouse and hu-
man dendritic cells. Nevertheless, Geissman at al. showed
that engagement of FcR specific for IgA does induce matu-
ration of human monocyte–derived dendritic cells (16).
Fc
 
 
 
R-mediated cell signaling results from a delicate bal-
ance between activation and inhibition signals triggered by
different Fc
 
 
 
Rs (6). The same immune complexes or op-
sonized particles may simultaneously engage activation and
inhibitory receptors. Coaggregation of these two types of
receptors results in inhibition of cell signaling. Therefore,
the outcome of Fc
 
 
 
R engagement depends on the relative
expression of activation and inhibitory receptors. In mouse,
IL4 (a cytokine used for the differentiation of monocytes
into dendritic cells) promotes the expression of Fc
 
 
 
RIIB,
an inhibitory Fc
 
 
 
R isoform (17). IFN-
 
 
 
, by contrast, pro-
motes the expression of activation Fc
 
 
 
R isoforms, such as
Fc
 
 
 
RI. In addition, the extent and specificity of Fc
 
 
 
R en-
gagement depend on the size of the immune complexes,
and on the isotype and species origin, of the Abs used to
form the immune complexes.
The pattern of Fc
 
 
 
R expression in vivo, in dendritic cell
subsets or during maturation, is unclear. Immature mono-
cyte– and CD34-derived dendritic cells express CD32 (18),
and occasionally, low levels of CD64. The relative expres-
sion of activation and inhibitory isoforms of CD32 (Fc-
 
 
 
RIIA and B/C, respectively) have not been analyzed.
Dendritic cells purified from the blood, in contrast, express
abundant CD64 (19). Therefore, it is not very surprising
that depending on the type and maturation status of the
dendritic cells used, the effect of immune complexes on
maturation may differ. Neither Fc
 
 
 
R expression, nor the
effect of immune complexes on dendritic cell maturation
have been yet analyzed in vivo (in mice or humans).
This point is particularly important, because different
subpopulations of dendritic cells and dendritic cells at dif-
ferent stages of maturation have different functions. For ex-
ample, mature dendritic cells induce T cell priming,
whereas immature dendritic cells are believed to induce
tolerance. In the context of autoimmunity, large immune
complexes uptake by dendritic cells could simultaneously
result in sensitization with autoantigens and induction of
maturation. These mature dendritic cells, bearing specific 
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peptides from autoantigens, could then contribute to break
tolerance and initiate the autoimmune responses. In the
case of solid tumors, when natural CTL responses are often
ineffective, the nature of the immune complexes and/or
the expression of inhibitory Fc
 
 
 
Rs in dendritic cells, could
prevent induction of maturation. The uptake of immune
complexes should then result in sensitization of immature
dendritic cells with tumor antigens, which could result the
induction of immunological tolerance.
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